“…However, the present prevalence was comparatively lower than the findings including a study done in Addis Ababa 15.7% [ 41 ] and 15% [ 42 ], and studies in the University of Gondar referral hospital 15.1 [ 43 ], 47.1% and 12.3% [ 33 , 44 ] respectively, Kenya 64.4% [ 45 ], Tanzania 25% [ 46 ], China 18.4% [ 47 ], Colombia 14% [ 48 ], Thailand 33.5% [ 49 ], Nepal 35% [ 50 ], a prospective observational cohort (n = 158) study in the developing Caribbean country 21.5% [ 51 ] and a study in England 47.6% [ 52 ]. The variation in the magnitude of immunological failure may be explained due to the difference in the socio-economic conditions, the definition of immunological failure, the duration of HAART [ 22 , 23 , 25 , 32 , 33 , 35 , 43 ], medication adherence [ 26 , 41 , 53 ], study design, sample size and setting [ 26 , 38 , 54 , 55 ], and immuno-virological discordance [ 15 , 17 , 18 , 21 , 38 , 56 ]. Also, the discrepancy can be explained by the emergence of drug-resistance among HIV-positive patients [ 10 , 16 , 37 , 40 ], their functional status [ 57 ], poor nutritional support [ 18 ], high burden of OIs [ 3 , 11 , 58 ], poor ART care, late initiation of HAART as well as ART-associated adverse reaction [ 23 ].…”